← Back to Search

Hepatic Artery Embolization for Liver Cancer

Phase < 1
Waitlist Available
Led By Scott M Thompson
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial is testing a new way to give the imaging agent 68Ga-PSMA to better detect prostate-specific membrane antigen (PSMA) positive liver cancer.

Eligible Conditions
  • Liver Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intraindividual intralesional difference in maximum standardized uptake value (SUVmax)
Secondary outcome measures
Difference in PSMA uptake measured by SUVmax (fold change, absolute difference) in the kidneys, spleen and salivary glands between I.A. and I.V. PSMA PET.
Incidence of adverse events
Intraindividual intralesional differences in tumor to background (TBR) of SUVmax

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (embolization, 68Ga-PSMA, PET/CT)Experimental Treatment3 Interventions
Patients undergoing clinically indicated hepatic artery embolization will receive 68Ga-PSMA intraarterially (IA) over 5 minutes. After 60-90 minutes, patients undergo PET/CT scan over 1 hour.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gallium Ga 68 Gozetotide
2020
Completed Phase 3
~1750
Positron Emission Tomography and Computed Tomography Scan
2015
N/A
~20

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,717 Previous Clinical Trials
40,953,364 Total Patients Enrolled
105 Trials studying Liver Cancer
27,028 Patients Enrolled for Liver Cancer
Mayo ClinicLead Sponsor
3,239 Previous Clinical Trials
3,771,599 Total Patients Enrolled
4 Trials studying Liver Cancer
9,361 Patients Enrolled for Liver Cancer
Scott M ThompsonPrincipal InvestigatorMayo Clinic in Rochester

Media Library

Hepatic Artery Embolization Clinical Trial Eligibility Overview. Trial Name: NCT05111314 — Phase < 1
Liver Cancer Research Study Groups: Diagnostic (embolization, 68Ga-PSMA, PET/CT)
Liver Cancer Clinical Trial 2023: Hepatic Artery Embolization Highlights & Side Effects. Trial Name: NCT05111314 — Phase < 1
Hepatic Artery Embolization 2023 Treatment Timeline for Medical Study. Trial Name: NCT05111314 — Phase < 1
~0 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top